2026 BD opportunity scan for Eilean Therapeutics LLC: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Eccogene (Shanghai) Co., Ltd: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale

2026 BD opportunity scan for E-Nitiate Biopharmaceuticals Hangzhou Co. Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and

2026 BD opportunity scan for Dyne Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Draig Therapeutics Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Dianthus Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Dendrogenix SA: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Delonix Bioworks Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Daré Bioscience, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Daewoong Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rati

2026 BD opportunity scan for D3 Bio (Wuxi) Co. Ltd: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for CSPC Ouyi Pharmaceutical Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rat